Multiple myeloma is by far the cancer most strongly and consistently associated with a low anion gap. The connection runs through the abnormal proteins this blood cancer produces, which alter the electrical balance of the blood in a way that pulls the anion gap downward. Other paraprotein-producing cancers can do the same, and any advanced cancer that drives albumin levels very low can shrink the gap through a different mechanism. The relationship between cancer and the anion gap is more specific and more clinically useful than most people realize.
Multiple Myeloma and the Paraprotein Mechanism
The anion gap is a calculated value from a basic metabolic panel. It reflects the difference between the major measured positive ions (sodium) and the major measured negative ions (chloride and bicarbonate) in your blood. In healthy people, this gap is usually around 10 to 12, representing unmeasured negative charges like those carried by albumin and other proteins. When the gap drops unusually low, something has added unmeasured positive charges to the blood or removed unmeasured negative charges.
In multiple myeloma, the “something” is a flood of abnormal immunoglobulin proteins called paraproteins. Myeloma cells are rogue plasma cells that churn out a single type of immunoglobulin at extremely high concentrations. At the normal pH of blood, certain paraproteins carry a net positive charge. Because the standard formula for the anion gap does not account for these extra positive charges, the calculated gap drops. In patients with high paraprotein levels, particularly those with immunoglobulin concentrations above about 4 grams per deciliter, the average anion gap was significantly lower than in people with normal immunoglobulin levels.1PubMed. Anion gap and immunoglobulin concentration The more paraprotein the cancer produces, the more the gap shrinks.
One study comparing myeloma patients to healthy controls found an average anion gap of about 7 in the myeloma group versus about 11 in the control group.2PubMed. Anion gap among patients of multiple myeloma and normal individuals That’s a meaningful shift, and in some patients the gap goes far lower than that.
Why IgG Myeloma Has a Bigger Effect Than IgA
Not all myeloma subtypes affect the anion gap equally, and this is where the chemistry gets interesting. Multiple myeloma is classified by the type of immunoglobulin the cancer produces: IgG, IgA, IgM, or light chain only. Each type behaves differently in blood.
IgG paraproteins carry a net positive charge at normal blood pH, acting as cations. That means they add unmeasured positive charges and pull the anion gap down. IgA paraproteins, by contrast, tend to carry a net negative charge, acting as anions. They can actually push the anion gap upward.3PubMed. Effect of chemotherapy on the anion gap in multiple myeloma This distinction between IgG and IgA behavior has been confirmed repeatedly, with studies showing a direct correlation between paraprotein concentration and anion gap in IgA myeloma (higher protein, higher gap) and an inverse correlation in IgG myeloma (higher protein, lower gap).4PubMed. Anion gap in multiple myeloma
The numbers bear this out concretely. In one study, the mean anion gap for IgG myeloma patients was about 6.8, while IgA myeloma patients averaged about 8.4, both lower than the control group’s average of about 11.2. But the IgG group showed a wider spread and consistently lower values.2PubMed. Anion gap among patients of multiple myeloma and normal individuals A lowered anion gap is considered a more specific feature of IgG-type myeloma than other subtypes.
A large study of monoclonal gammopathies looked at the anion gap across different immunoglobulin types. The gap was decreased in about 22 percent of patients with IgG gammopathies, while it was actually increased in about 31 percent of those with IgA gammopathies. Patients with IgM gammopathies showed no consistent effect on the gap at all, and light chain gammopathies went in both directions without a clear pattern.5PubMed Central. The anion gap and routine serum protein measurements in monoclonal gammopathies If you’re looking at a low anion gap specifically as a cancer clue, IgG myeloma is the standout.
How the Gap Tracks With Disease Stage
The anion gap doesn’t just flag the presence of myeloma; it tends to reflect how advanced the disease is. As the cancer progresses and paraprotein levels climb, the gap drops further. In one study that stratified patients by clinical stage, the average anion gap was about 8.7 in stage I disease, about 7.9 in stage II, and about 5.7 in stage III.2PubMed. Anion gap among patients of multiple myeloma and normal individuals That stepwise decline mirrors the rising paraprotein burden as myeloma advances.
This relationship is strong enough that some researchers have suggested tracking the anion gap over time to monitor how a patient is responding to chemotherapy. If treatment is working and the paraprotein load drops, the gap should rise back toward normal. Serial measurements of the anion gap could serve as a simple, inexpensive way to gauge treatment response alongside other markers.3PubMed. Effect of chemotherapy on the anion gap in multiple myeloma It’s not a replacement for specialized testing, but it’s information that’s already sitting in routine blood work.
When the Gap Goes Negative
In extreme cases, the anion gap doesn’t just go low; it drops below zero. A negative anion gap is a mathematically “impossible” result under normal physiology and almost always points to a massive unmeasured cation load. Case reports describe young patients with aggressive myeloma presenting with negative anion gaps alongside striking electrolyte shifts like very low sodium levels. In one such case, the myeloma protein itself was identified as the cause, acting as a potent cation at physiological blood pH and completely overwhelming the normal balance of charges.6Clinical Chemistry. Negative anion gap in a young adult with multiple myeloma
A negative anion gap on a routine lab panel is rare enough that it should always prompt further investigation. While lab error or certain drug exposures can occasionally cause it, a paraprotein-producing cancer is high on the list of real pathological explanations.
Other Blood Cancers That Produce Paraproteins
Multiple myeloma gets the most attention, but it isn’t the only blood cancer that pumps out abnormal immunoglobulin. Lymphoplasmacytic lymphoma, sometimes called Waldenström macroglobulinemia, is a slow-growing lymphoma that produces large quantities of IgM. However, the data on IgM’s effect on the anion gap is less straightforward. As noted earlier, IgM gammopathies did not consistently shift the anion gap in either direction in at least one large study. This makes lymphoplasmacytic lymphoma a less reliable cause of a low anion gap than IgG myeloma, though individual cases have been reported where IgM-producing cancers were found after a low gap was discovered.
Other B-cell lymphomas and chronic lymphocytic leukemia can occasionally produce monoclonal proteins, but the volumes are usually too low to meaningfully shift the anion gap. Among cancers, IgG-producing myeloma occupies a category by itself when it comes to this particular lab finding.
It’s also worth noting that monoclonal gammopathy of undetermined significance, a precancerous condition where paraproteins are present but the full cancer has not developed, can lower the anion gap through the same mechanism. The presence of a low gap should prompt evaluation for both overt myeloma and its precursor states.
Low Albumin as a Separate Pathway
Paraproteins are the most specific cancer-related cause of a low anion gap, but they aren’t the only route. Albumin, the most abundant protein in blood, normally carries a negative charge and makes up a large chunk of the unmeasured anions that the gap reflects. When albumin drops, the gap shrinks.
Many advanced cancers drive albumin levels down through poor nutrition, chronic inflammation, or direct effects on liver function. Kidney damage from cancer or its treatment can also cause massive protein loss in urine. In nephrotic syndrome, where large amounts of protein spill into urine, the anion gap drops significantly. One study found that the low gap in nephrotic patients correlated with low total serum protein and especially low albumin below about 1.5 grams per deciliter, but not with cholesterol or immunoglobulin levels. The researchers concluded that hypoalbuminemia was the major driver of the low gap in these patients.7PubMed. Anion gap in nephrotic syndrome
This pathway is less specific than the paraprotein mechanism. A low anion gap from hypoalbuminemia alone doesn’t point to any particular cancer. Instead, it signals that the patient is in poor nutritional or metabolic shape, which can happen in advanced cancer of many types. If you see a low anion gap in a patient with known advanced cancer and low albumin, the albumin is probably the explanation. If albumin is normal and the gap is still low, paraprotein-producing cancers should be investigated.
The Albumin-Corrected Anion Gap
Because albumin has such a strong influence on the anion gap, clinicians sometimes use a corrected version. The albumin-corrected anion gap adjusts the raw number upward to account for low albumin, essentially asking: “What would the gap be if albumin were normal?” The standard correction adds about 2.5 points to the gap for every gram per deciliter that albumin falls below roughly 4.4.8PubMed Central. Albumin-corrected anion gap and risk of mortality among US adults
This correction matters for cancer patients because many of them have low albumin from their disease. If a myeloma patient has both high paraprotein levels and low albumin, the raw anion gap reflects both influences stacked on top of each other. The corrected version can help tease apart how much of the drop is from albumin alone versus how much is from the paraprotein. It also prevents clinicians from overlooking a hidden high anion gap acidosis in a cancer patient whose albumin is so low that the raw number looks deceptively normal.
When a Low Anion Gap Leads to a Cancer Diagnosis
Sometimes a low anion gap on routine blood work is the first clue that something is wrong, before any cancer symptoms have appeared. In one reported case, a patient with sickle cell disease developed altered mental status, and a routine lab finding of a low anion gap pointed clinicians toward multiple myeloma as the underlying cause. That finding directed the diagnostic workup and led to timely treatment.9Journal of Medical Case Reports. Altered mental status and low anion gap in a patient with sickle cell anemia: a case report
A review article from the Cleveland Clinic highlighted that evaluating a low anion gap systematically, with a stepwise approach to diagnostic testing, can help clinicians build a useful differential diagnosis rather than dismissing the finding as irrelevant.10PubMed Central. Evaluating a low anion gap: A practical approach The anion gap is calculated automatically on most metabolic panels, so the information is already there. The challenge is recognizing that a low value deserves the same attention that a high one typically gets.
In practice, finding a low anion gap without an obvious explanation like severe hypoalbuminemia should prompt a clinician to check serum protein levels and, if those are elevated, to order protein electrophoresis. That test separates proteins by type and can identify a monoclonal spike suggestive of myeloma or a related disorder. From there, further workup including bone marrow biopsy and imaging can confirm or rule out cancer.
Polyclonal Immunoglobulin Elevations
The discussion so far has focused on monoclonal proteins, the single-type immunoglobulins produced by a clone of cancerous or precancerous cells. But the anion gap can also drop when overall immunoglobulin levels rise across multiple types, a situation called polyclonal hypergammaglobulinemia. In a study of 83 patients with diffuse polyclonal elevations in immunoglobulin concentration above 3 grams per deciliter, the mean anion gap was significantly lower than in patients with normal immunoglobulin levels.1PubMed. Anion gap and immunoglobulin concentration
Polyclonal elevations are most commonly triggered by chronic infections, autoimmune diseases, and liver disease rather than by cancer. However, certain cancers can provoke a polyclonal immune response, particularly lymphomas and some solid tumors that stimulate the immune system broadly. In those patients, a low anion gap could reflect the polyclonal protein load rather than a monoclonal paraprotein. The distinction matters because the diagnostic workup and treatment are entirely different. Protein electrophoresis is again the key test: a sharp monoclonal spike points toward myeloma or a related clonal disorder, while a broad elevation across the gamma region suggests a reactive, polyclonal process.
Non-Cancer Causes to Keep in Mind
A low anion gap is not always about cancer. Several non-malignant conditions can produce the same lab finding, and understanding them helps avoid unnecessary panic when the number shows up on a report.
- Hypoalbuminemia from liver disease or malnutrition: as described above, any condition that drops albumin will lower the gap.
- Lithium use: lithium is a positively charged ion that is not included in the standard anion gap formula, so high lithium levels add unmeasured cations and shrink the gap.
- Severe hyponatremia: very low sodium can compress the calculated gap, sometimes in combination with paraproteins as seen in some myeloma cases.
- Lab error: certain sample-handling issues, including very high lipid levels that interfere with electrolyte measurement, can produce a spuriously low anion gap.
In someone who is not on lithium, has normal albumin, and has no obvious lab artifact, a persistently low anion gap should raise suspicion for a paraprotein-producing disorder. The lower the gap and the more it persists across repeated lab draws, the more seriously that possibility deserves investigation. A one-time mildly low reading can often be dismissed. A repeated finding in the low single digits, or a negative gap, virtually demands a workup for myeloma or a related condition.